PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 19

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/627,499		
Filing Date	07/25/2003		
First Named Inventor	Kink et al.		
Art Unit	1646		
Examiner Name	Xie		
Attorney Docket Number	OPHD0-8311		

U. S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where **Publication Date** Examiner **Document Number** Relevant Passages or Relevant MM-DD-YYYY Applicant of Cited Document Initials' Figures Appear Number-Kind Code² (F known) US-Kilbourn et al. whole document 12 08/02/1994 5,334,380 us. US-US-US-US-IIS. US-US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS						
	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.
		Country Code ³ Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	F
						┢
					ļ	┢
	-					
						L
	T					L

Examiner	Date	"12/2
	Considered	(4/13/0/
Signature I	College	46.56.51
•		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No.: OPHD-08311 Serial No.: 10/627,499 U.S. Department of FORM PTO-1449 Commerce Office Applicant: John A. Kink et al. (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) Group Art Unit: 1646 Filing Date: 7/25/2003 (37 CFR § 1.98(b)) **YT DOCUMENTS WIRL** Serial / Patent Examiner Applicant / Patentee Class Subclass Filing Date Issue Date Number Initials XZ Hardie 424 85 4/05/82 10/16/84 4,477,432 514 256 1/06/95 2/18/97 Smith et al. 2 5,604,231 5/18/95 514 362 5,614,540 3/25/97 Christensen 5/05/95 530 388.15 Boyle et al. 5,654,407 8/05/97 12/13/91 435 240.27 Barbanti et al. 7/25/95 5,436,154 514 231.5 10/02/92 Kaplan et al. 1/31/95 6 5,385,901 8/29/85 530 43 Rubin et al. 4,870,163 9/26/89 424 133.1 2/04/94 8/12/97 Le et al. 5,656,272 08/04/86 424 85 6/30/87 Hassig 4,676,982 5/02/85 435 68 6/30/87 Mark et al. 4,677,064 10 6/19/84 87 424 Strolle et al. 4,748,018 5/31/88 11 85.8 4/01/91 424 1/14/92 Tokoro 12 5,080,895 12/20/85 69.5 435 1/30/96 Allet et al. 5,487,984 13 5/05/95 139.1 424 9/30/97 Aggarwal et al. 5,672,347 14 3/01/95 145.1 1/13/98 424 Fong et al. 5,707,622 15 12/05/94 151.1 Sterling et al. 424 5/19/98 5,753,228 16 424 187.1 7/30/96 6/30/98 Greenblatt et al. 5,772,999 17 6/07/95 530 388.23 5,795,967 8/18/98 Aggarwal et al. 18 9/09/93 423 530 5/30/95 Emery et al. 5,420,253 19 FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS Translation Document Class Subclass Yes No Country / Patent Office **Publication Date** Number 1/2 PCT · 04/09/98 WO98/14209 20 WIPO WO96/33204 10/24/96 21 WO97/15327 05/01/97 PCT 22 **EPO** EP 0 155 549 B1 03/20/91 23 OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Polson et al., "Antibodies to Proteins from Yolk of Immunized Hens," Immunol. Comm., 9:495-514 (1980) XZ 24 Okayasu et al., "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice," Gastroenterology, 98:694-702 (1990) 25 Kojouharoff et al.,"Neutralization of tumour necrosis facto (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," Clin. Exp. Immunology, 107: 353-358 (1997) 26 Olson et al., "Antiserum to Tumor Necrosis Factor and failure to Prevent Murine Colitis," J. Pediatric Gastroenterology and Nutrition 21: 410-418 27 Stack et al., "The Effects of CDP571, An Engineered Human IgG~4 Anti-TNF~ Antibody in Crohn's Disease", Gastroenterology, 110:A1018 (1996)13/07 Date Considered: Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with **EXAMINER:** next communication to applicant.

FORM PTO-1449		U.S. Department of	Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499	
Commerce		Patent and Trademark Office	Applicant: John A. Kink et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		LOSURE STATEMENT BY APPLICANT			
(Use Several Sheets If Necessary) (37 CFR § 1.98(b))			Filing Date: 7/25/2003	Group Art Unit: 1646	
OTHER DOCUMENTS (Including Author, Title,			ate, Relevant Pages, Place of Publication)		
XZ	29	Rutgeerts et al., "Retreatment with Anti-TNF- Chimeric Antibody (cA2) Effectively maintains cA3-Induced remission in Crohn's Disease," Gastroenterology 112:A1078 (1997)			
	30	Van Dullemen et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," Gastroenterology 109:129-138 (1995)			
	31	Targan et al.,"A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ~ for Crohn's Disease," New England Journal of Medicine, 337:1029-1035 (1997)			
	32	Plevy et al.," A Role for TNF-« and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," Journal of Immunology, 6277-6282 (1997)			
	33	Sartor, "Current Concepts of the Etiology and Pathogenesis of Ulo (1995)	cerative Colitis and Crohn's Disease," Inflami	natory Bowel Disease, 24:475-507	
	34	Sartor, "Pathogenesis and Immune Mechanisms of Chronic Inflan	nmatory Bowl Diseases," Gastroenterology,	92:5S-11S (1997)	
	35	Robinson, "Optimizing Therapy for Inflammatory Bowel Disease	," American Journal of Gastroenterology,	92:12-17 (1997)	
	36	Targan and Shanahan, "Pseudomembranous Colitis and Clostrid 51:743-755 (1994)	lium Difficle Infection," Inflammatory Bowel	Disease From Bench to Bench,	
	37	Ogorek and Fisher, "Differentiation Between Chrohn's Disease a (1994)	nd Ulcerative Colitis," in Inflammatory Bowe	el Disease, Katz, ed., 78:1249-1257	
	38	(1994) Cameron, "Anti-TNF-∝ treatments set to mop up in rheumatoid arthritis," Research and Development, pp.9-10 (1998)			
	39	Elliott et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis facto \(\pi\) (cA2) verus placebo in rheumatoid arthritis," Lancet, 344:1105-1110 (1994)			
	40	Elliott et al., "Repeated therapy with monoclonal antibody to tumour necrosis factor \(\pi\) (cA2) in patients with rheumatoid arthritis," Lancet 344:1125-1127 (1994)			
	41	Gibson, "Inflammatory Bowel Disease Current Concepts in Path	ogenesis and Therapy," Clin. Immunother., 2	(2):135-160 (1994)	
	42	Bell and Wallace, "Infammatory Bowel Disorders Current and Fr	uture Drugs that Modulate Adhesion Molecu	les," Biodrugs, 7(4):273-284 (1997)	
	43	Opal et al., "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," J. Infect. Dis., 173:1415-1421(1996)			
	44	Russell et al., "Combined Inhibition of Interleukin-1 and Tumor J. Infect. Dis., 171:1528-1538(1995)	Necrosis Factor in Rodent Endotoxemia: Imp	proved Survival and Organ Function,"	
	45	Levine et al., "Intravenous Immunoglobulin Therapy for Active, Extensive and Medically Refractory Idiopathic Ulcerative or Crohn's Colitis" Am J. Gastroenterol, 87:91-100 (1992)			
	46	Neurath et al., "Predominant Pathogenic role of Tumor Necrosis	Factor in Experimental Colitis in Mice, " Eu	r J Immunol 27:1743-1750 (1997)	
	47	Neurath et al., "Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in mice," J Exp Med 182:1281-1290 (1995)			
	48	Feldmann et al., "Cytokine Expression and Networks in Rheumatoid Arthritis: Rationale for Anti-TNFanpha Antibody Therapy and its Mechanism of Action," J Inflamation 47:90-96 (1996)			
·	49	Reimund et al., "Increased production of tumor necrosis factor-alpha, interleukin-1-beta and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease" Gut 39:684-689 (1996)			
	50	Duchmann et al., "Tolerance toweards resistant intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12," Eur J Immunol 26:934-938 (1996)			
	51	Tsubokura et al., "Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni-infected chickens," Clin Exp Immunol 108:451-455 (1997)			
	52	Nicholls et al., "Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea," J Clin Path 46:757-760 (1993)			
	53	Tjellström et al., "Oral immunoglobulin treatment in Crohn's dis			
	54	Rubalteli et al., "Prevention of necrotizing enterocolitis in neonal 143 (1991)		ric IgG," Dev Pharmacol Ther 17:138-	
Examiner: Date Considered: 4/13/07					
EXAMINE	R: In	nitial citation considered. Draw line through citation if not in conforext communication to applicant.	mance and not considered. Include copy of t	his form with	

FORM PTO-1449		U.S. Department of	Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499	
Commerce (Modified)		Patent and Trademark Office	Applicant: John A. Kink et al.		
INFORMATION D	ISCL	OSURE STATEMENT BY APPLICANT			
(Use Several Sheets)	If Nec	essary)	Filing Date: 7/25/2003	Group Art Unit: 1646	
(37 CFR § 1.98(b))		OTHER DOCUMENTS (Including Author Title D			
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)			1-1058 (1997)		
5	Armstrong et al., "Tumor necrosis factor and intianumanity bower disease," british four hardy stargery of the second of the seco				
50	6	Monteleone et al., "Interleukin 12 (IL-12) is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells (IPMCs)," Gastroenterology 112:1169-1178 (1997)			
51	7	Starnes et al., "Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice" J Immuno 12:4185-4191 (1990)			
	8.	Doherty et al., "Evidence for IFN-gama as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha" J Immuno 5:1666-1670 (1992)			
5	9	Manthey et al., "The role of cytokines in host responses to endotoxin" Reviews in Med Microbio 3:72-79 (1992)			
64	0	Dalekos, et al., "High concentrations of soluable interleukin-2 receptors and interleukin-6 in active ulcerative cells" Hellenic J Gastro 8:319-327 (1995)			
6	1	Evans, et al., "Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571" Aliment Pharmacol Ther 11:1031-1035 (1997)			
6	2	Hoang, et al., "Symposium: Role of cytokines in inflammatory be	owel disease" Acte Gastro-Enterologica Belg	ica 57:219-223 (1994)	
6	3	van Hogezand, et al., "Selective immunomodulation in patients with inflammatory bowel disease-future therapy or reality?" Netherlands J of Med 48:64-67 (1996)			
6	4	Zacharchuk et al., "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," PNAS USA 80:6341-6345 (1983)			
6	5	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," Dissertation Abstract (1983)			
6	6	Pennica et al., "Human humor necrosis factor: precursor structure, expression and homology to lymphotoxin," Nature 312:724-729 (1984)			
, 6	7	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," Dissertation Abstract. (1980)			
J 6	8	Beck et al., "Cytokines in inflammatory bowel disease," Mediato			
6	9	•			
7	0				
	'1				
	2				
	·3				
	4				
	75				
	6				
	77			·	
	8				
	19				
Examiner:			Date Considered: 4/13	107	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					